Thermo Fisher Scales Solvent-Free Drug Production Tech
The company targets 2027 for commercial-scale deployment of tools designed to accelerate small-molecule drug development.
Updated on Oct. 27, 2026 in Biotech
Live Poll
Do you believe new pharmaceutical manufacturing technologies will help lower drug costs for patients?
Thermo Fisher Scientific recently demonstrated a predictive modeling platform and solvent-free manufacturing process designed to accelerate drug development. The company currently plans to scale these technologies to commercial production levels by 2027.
Why it matters
Approximately 90% of small-molecule drugs face solubility challenges, making efficient formulation selection and manufacturing critical for drug delivery. These tools aim to reduce development timelines by streamlining the path from candidate selection to clinical testing.
The Quadrant 2 platform has categorized over 400 molecules, while the KinetiSol technology achieved a 13.8-fold bioavailability increase for abiraterone. KinetiSol processes drugs in 10 to 20 seconds, significantly faster than traditional heating methods.
The players
Thermo Fisher Scientific
A global leader in laboratory equipment, analytical instruments, and contract development and manufacturing services for the pharmaceutical industry.
AustinPx
A pharmaceutical manufacturing and technology company specializing in bioavailability enhancement for poorly soluble drug compounds.
The details
KinetiSol technology creates amorphous solid dispersions—a technique that increases the surface area of a drug to improve absorption—by using system-generated shear rather than traditional solvents or external heat. This mechanical processing allows for rapid, thermal-degradation-free manufacturing. The Quadrant 2 platform complements this by using API (Active Pharmaceutical Ingredient) properties to rank candidate technologies into three tiers, directing developers toward the most viable formulation strategy.
Timeline
June 2026: AustinPx installed KinetiSol hardware at sites in Bend, Oregon and Cincinnati, Ohio.
September 2026: The FDA granted KinetiSol technology Advanced Manufacturing Technology designation.
October 2026: Thermo Fisher presented predictive modeling findings at AAPS PharmSci 360.
2027: Thermo Fisher plans to initiate commercial-scale production using KinetiSol.
The Tech Race
This development aligns with the FDA's Advanced Manufacturing Technology designation program, which encourages the adoption of novel, efficient production methods. Thermo Fisher is positioning its KinetiSol platform to compete against traditional, solvent-heavy manufacturing standards.
For pharmaceutical developers, these technologies offer a path to reduce clinical development timelines to as little as 7 to 8 months. The shift toward solvent-free processing may eventually streamline the manufacturing of high-potency drugs that are currently difficult to stabilize.
The takeaway
Thermo Fisher is aggressively moving to modernize small-molecule formulation through predictive software and rapid, mechanical manufacturing. Industry observers should watch for the 2027 commercial-scale rollout in Cincinnati to determine if these gains hold at high manufacturing volumes.
What happens next
Thermo Fisher plans to deploy a late-stage KinetiSol Compounder at its Cincinnati facility in the first or second quarter of 2027.
Further reading
For broader trends in pharmaceutical process innovation, see our coverage in Biotech.
Source note: This article includes information reported by BioPharm International.
Live Poll
Do you believe new pharmaceutical manufacturing technologies will help lower drug costs for patients?
